MedCity News September 8, 2025
Despite achieving statistically signficant improvement in progression-free survival in North American and European patients, Summit’s drug ivonescimab fell short of the other Phase 3 goal measuring overall survival. It’s the first Phase 3 readout for an emerging class of bispecific antibodies that treat cancer by blocking two targets, PD-1 and VEGF.
A closely watched Summit Therapeutics lung cancer drug showed trending improvement on a pivotal study’s measure of how long patients treated with the therapy lived, but the result in the final analysis in Western patients was not enough to be statistically significant — a shortfall that could keep the blockbuster hopeful from securing U.S. and European regulatory approvals.
The results are important because they’re the first Phase 3 data...
Today's Sponsors
Today's Sponsor